论文部分内容阅读
比较石杉碱甲胶囊和片剂对阿尔采末病的疗效和安全性.方法:采用双盲双模拟法将入选的60例阿尔采末病人随机等分两组,胶囊组每次口服石杉碱甲胶囊4粒和安慰剂片4片;片剂组每次口服石杉碱甲片(哈伯因)4片和安慰剂胶囊4粒,两组均每日两次,60日为一疗程.所有病人都测量WMS,MMS,HDS-R,IADL,GBS痴呆综合征量表和各种检查以及氧自由基.结果:两组所有心理量表值疗后均有显著改善(P<0.01),而两组间无明显差异(P>0.05),且等效检验合格;两组的自由基病理变化疗后也明显减轻,但也无组间差异(P>0.05);两组未发生严重不良反应.结论:石杉碱甲胶囊和片剂治疗阿尔采末病时疗效和安全性相等。
To compare the efficacy and safety of huperzine A capsules and tablets on Alzheimers disease. Methods: Sixty patients with Alzheimer’s disease were randomly divided into two groups by double-blind double-dummy method. The capsule group received 4 huperzine capsules and 4 placebo tablets at a time. 4 tablets of alkali tablets (Hubble) and 4 capsules of placebo capsules, two groups were twice daily, 60 days for a course of treatment. All patients measured WMS, MMS, HDS-R, IADL, GBS dementia syndrome scales and various examinations as well as oxygen free radicals. Results: All the psychometric scales of both groups were significantly improved after treatment (P <0.01), but there was no significant difference between the two groups (P> 0.05), and the equivalent test was acceptable. The free radical pathology Changes were also significantly reduced after treatment, but no difference between groups (P> 0.05); two groups did not occur serious adverse reactions. Conclusion: Huperzine capsules and tablets are equally effective and safe in the treatment of Alzheimer’s disease.